Oncologic outcome of conservative surgery with adjuvancy in breast cancer, Hospital San Felipe, Tegucigalpa

Abstract

Background: Breast cancer is the most frequently diagnosed malignancy in women, representing almost 1 in every 4 cancer cases. Objective: To describe the oncological results of patients treated with conservative surgery and adjuvant treatment for breast cancer clinical stages I-II, Hospital San Felipe, Tegucigalpa. 2017-2019. Methods: Cross-sectional descriptive retrospective study. Review of clinical records of patients with new diagnosis of breast cancer. Sociodemographic data, preand post-operative clinical stage, treatment and survival were register. Results: Of 49 patients, 59.2% (29) >50 years, 71.4% (35) urban origin, 61.2% (30) stage IIA; the therapeutic modalities were radiotherapy 73.5% (36), endocrine therapy 69.4% (34), chemotherapy 40.8% (20). The most frequent combination was radiotherapy/endocrine therapy in 46.9% (23); 26.5% (13) received monotherapy. The mean time to start radiotherapy was 25 weeks (range 4-90 weeks) and chemotherapy was 13 weeks (range 4-35 weeks). According to the postoperative clinical stage, survival at 36 months in stage IA and IIB with adjuvancy was 100.0% (5) and 86.0% (12), respectively. The overall survival at 36 months was 95.9% (47). Discussion: The overall survival identified is comparable to studies that follow international guidelines. We recommend implementing the recommendations of the international guidelines for early-stage breast cancer management, in which adjuvancy should begin in a period no longer than 8 postoperative weeks. This management would contribute to reduce the morbidity and psychosocial impact of more radical therapeutic approaches. It is necessary and urgent to have equipment and adjuvant drugs according to scientific and technological advances.